Andra AP fonden Boosts Stock Position in Natera, Inc. $NTRA

Key Points

• Andra AP fonden increased its Natera stake by 16.9% in the second quarter, adding 14,000 shares to own 96,737 shares worth approximately $26.3 million. Institutional investors collectively hold 99.9% of Natera’s stock.
• Natera reported quarterly revenue of $752.75 million, up 37.7% year over year and above analyst estimates, while its adjusted loss of $0.47 per share slightly beat expectations.
• Natera shares recently traded near their 52-week high at $386.79, and analysts maintain a “Moderate Buy” consensus with an average price target of $330.83. Company insiders have sold shares in recent months under pre-arranged trading plans.

Andra AP fonden boosted its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 16.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 96,737 shares of the medical research company's stock after purchasing an additional 14,000 shares during the period. Andra AP fonden owned about 0.07% of Natera worth $26,259,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Trust Co. of Vermont bought a new stake in shares of Natera in the 2nd quarter worth approximately $26,000. Elevation Wealth Partners LLC purchased a new stake in Natera in the second quarter worth $30,000. Continuum Advisory LLC bought a new stake in Natera in the second quarter valued at $33,000. Reflection Asset Management bought a new stake in Natera in the fourth quarter valued at $29,000. Finally, Rakuten Securities Inc. purchased a new position in Natera during the 2nd quarter valued at $35,000. Institutional investors own 99.90% of the company's stock.

Natera Stock Performance

Shares of Natera stock traded up $16.15 during trading on Tuesday, hitting $386.79. The company's stock had a trading volume of 605,328 shares, compared to its average volume of 1,361,379. The company has a fifty day simple moving average of $307.40 and a two-hundred day simple moving average of $248.17. The company has a market capitalization of $55.75 billion, a PE ratio of -284.48 and a beta of 1.54. Natera, Inc. has a 52 week low of $157.43 and a 52 week high of $389.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same quarter in the previous year, the firm posted ($0.74) earnings per share. Natera's quarterly revenue was up 37.7% on a year-over-year basis. As a group, analysts predict that Natera, Inc. will post -1.02 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Canaccord Genuity Group set a $375.00 target price on shares of Natera in a research report on Friday, August 7th. Rothschild & Co Redburn began coverage on shares of Natera in a research note on Tuesday, September 8th. They issued a "buy" rating and a $385.00 price target for the company. The Goldman Sachs Group started coverage on shares of Natera in a report on Friday, June 5th. They issued a "neutral" rating and a $245.00 price objective for the company. JPMorgan Chase & Co. upped their target price on Natera from $315.00 to $360.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Finally, Zacks Research upgraded Natera from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $330.83.

Insider Buying and Selling

In related news, CEO Steven Chapman sold 1,698 shares of the company's stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $320.99, for a total value of $545,041.02. Following the sale, the chief executive officer owned 98,199 shares in the company, valued at $31,520,897.01. This represents a 1.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John Fesko sold 6,517 shares of Natera stock in a transaction on Monday, August 10th. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01. Following the transaction, the insider owned 197,257 shares of the company's stock, valued at $63,424,043.21. The trade was a 3.20% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 68,242 shares of company stock valued at $19,301,534. 5.05% of the stock is owned by company insiders.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services based on cell-free DNA and other genomic technologies. The company focuses on reproductive health, oncology and organ health, providing tests intended to support screening, diagnosis, treatment planning and disease monitoring.

Its reproductive health portfolio includes Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.